Merck chief quits as further material on Vioxx emergesBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7500.1101-a (Published 12 May 2005) Cite this as: BMJ 2005;330:1101
- Ray Moynihan
The chief executive officer and chairman of Merck, Raymond Gilmartin, resigned unexpectedly last week, the same day a damning US Congress report on the company was released.
Even though Mr Gilmartin stepped down hurriedly a year ahead of schedule, Merck's official position is that the resignation was not connected to the growing global controversy over its anti-arthritis drug rofecoxib (Vioxx), which was withdrawn from the market late last year, after studies produced evidence …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial